CLASS II Drug recall · Reported 24 Jun 2020 · FDA Enforcement Report

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg recalled

Apotex is recalling Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, distributed nationwide in the US. The recall was initiated on 27 May 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll lots remaining within expiry
Quantity recalled305,963 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1303-2020
FDA event ID
85772
Recalling firm
Apotex, North York
Classification
Class II
Status
Completed
Recall initiated
27 May 2020
FDA classified
12 Jun 2020
Reported
24 Jun 2020
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Nitrosamine Impurity

Timeline

27 May 2020Recall initiated by company
12 Jun 2020Classified by FDA+16 days
24 Jun 2020Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, 100 count bottles, Rx Only Manufactured by: Apotex, Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326 NDC 60505-0260-1

Where it was distributed

Nationwide.

Nationwide

Questions about this recall

Is Metformin Hydrochloride Extended-Release Tablets, USP 500 mg recalled?

Yes. Apotex recalled Metformin Hydrochloride Extended-Release Tablets, USP 500 mg on 27 May 2020. The recall is Class II and its status is Completed. Recall number D-1303-2020.

Why was it recalled?

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels

Which lots are affected?

All lots remaining within expiry

Where was it sold?

Nationwide.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Apotex

All 75
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPaxil CR, Paroxetine, Extended-Release Tablets, 5mg recalled by ApotexPaxilApotexPotency & AssayNationwide
DrugCLASS IIDesmopressin Nasal Spray, USP, 10 mcg/ bottle (50 doses) recalledApotexOtherNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution 2%/0.5%* recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide

Other Metformin recalls

All 57